Cellular senescence represents a key hallmark of biological aging that accelerates neurodegeneration. In recent years, researchers have actively explored senolytics in Alzheimer's disease to eliminate dysfunctional, proinflammatory cells. Early human studies evaluate whether repurposed senolytic agents can modulate underlying neuropathology. A pioneering phase 1 trial investigated dasatinib plus quercetin in older adults with mild Alzheimer's disease. While initial findings established central nervous system penetration and safety, identifying reliable surrogate markers remains vital for clinical progress.

Investigating Senolytics in Alzheimer's Disease

Senescent cells permanently arrest division yet remain metabolically active. Consequently, these cells secrete damaging cytokines, chemokines, and matrix metalloproteinases, termed the senescence-associated secretory phenotype. In the human brain, this chronic secretory state exacerbates tau hyperphosphorylation, microglial exhaustion, and progressive synaptic dysfunction. Therefore, targeting senescent cells through intermittent pharmacological therapy offers a promising neuroprotective strategy. The combination of dasatinib, a tyrosine kinase inhibitor, and quercetin, a plant flavonoid, disrupts key pro-survival pathways in senescent cells. Preclinical rodent models demonstrated that this regimen cleared neurofibrillary tangles, reduced amyloid pathology, and preserved spatial memory. However, translating these benefits to human patients requires rigorous clinical evaluation. The open-label phase 1 SToMP-AD trial enrolled five older participants with early symptomatic Alzheimer's disease to assess safety. Dasatinib successfully crossed the blood-brain barrier without triggering severe adverse events. Nevertheless, clinicians currently lack standardized biofluid markers reflecting cellular senescence burden in living individuals. To address this need, investigators conducted exploratory analyses of blood, cerebrospinal fluid, and urine samples. These multi-omic evaluations provide crucial baseline data to guide future phase 2 clinical trial designs.

Targeted Cytokine and Chemokine Modulation

To evaluate biological responses, investigators utilized high-sensitivity immunoassays examining inflammatory signaling cascades before and after senolytic treatment. Notably, biofluid analyses revealed significant post-treatment elevations in plasma fractalkine, also designated CX3CL1, alongside increased matrix metalloproteinase-7. Furthermore, cerebrospinal fluid profiling demonstrated a measurable increase in interleukin-6 levels following therapy. In neural tissue, fractalkine functions as an essential regulatory chemokine that coordinates microglial activation and maintains neuroprotective surveillance. Therefore, rising circulating fractalkine concentrations may indicate beneficial shifts in neuroimmune homeostasis or enhanced cellular shedding. Similarly, matrix metalloproteinases mediate tissue remodeling and degrade damaged extracellular structures surrounding cleared senescent cells. While elevated interleukin-6 often suggests inflammatory signaling, transient post-treatment spikes may reflect acute clearance dynamics as senescent cells undergo apoptosis. In addition, these distinct cytokine fluctuations illustrate that senolytic therapy does not induce uniform immunosuppression. Instead, the intervention promotes selective immune remodeling across central and peripheral compartments. Consequently, tracking these specific inflammatory mediators provides critical insight into human pharmacodynamics during senolytic administration.

Stability of Core Amyloid and Tau Biomarkers

Mass spectrometry analyses provided precise quantitative evaluations of classic neurodegenerative analytes in the cerebrospinal fluid. Interestingly, the investigation demonstrated stable levels of amyloid beta 40, amyloid beta 42, and total tau proteins between baseline and post-treatment assessments. Thus, a short course of senolytic therapy did not abruptly alter established cerebral amyloid plaques or neurofibrillary tangles. Furthermore, investigators observed that urinary metabolites remained unchanged throughout the therapeutic protocol. Mass spectrometry lipidomic profiling revealed only modest treatment-associated alterations in circulating lipid species. These stable biomarker profiles offer reassuring evidence regarding the biological safety of intermittent dasatinib and quercetin dosing. Specifically, rapid senescent cell clearance did not trigger neurochemical instability or acute neurotoxicity. In addition, clinicians must recognize that clearing senescent cells aims to halt progressive secondary injury rather than immediately dissolve dense protein aggregates. Because Alzheimer's pathology accumulates over decades, meaningful reductions in core protein burden will likely require extended treatment durations. Therefore, stable core biomarker levels confirm that senolytics maintain fundamental biochemical homeostasis while initiating microenvironmental changes.

Transcriptomic Downregulation of Inflammatory Pathways

Beyond biofluid proteomics, the researchers performed targeted transcriptomic analysis on peripheral blood mononuclear cells isolated from study participants. Remarkably, this profiling demonstrated significant downregulation of multiple key proinflammatory transcription factors and immune mediators. Specifically, the treatment suppressed the expression of essential immediate early genes, including FOS, FOSB, JUN, and JUNB. These genes assemble the activator protein 1 transcription factor complex, which directly drives chronic senescence-related inflammation. In addition, transcriptomic data revealed substantial downregulation of interleukin-1 beta, interleukin-8, and prostaglandin-endoperoxide synthase 2, also known as cyclooxygenase-2. Therefore, intermittent senolytic therapy effectively dampened systemic inflammatory tone at the cellular level. This systemic modulation carries profound clinical significance because peripheral inflammation actively exacerbates blood-brain barrier dysfunction and neuroinflammation. Furthermore, peripheral blood mononuclear cells offer an accessible, minimally invasive liquid biopsy source for clinical monitoring. Clinicians can track transcriptomic changes across repeat cycles without requiring invasive lumbar punctures. Consequently, peripheral transcriptomic signatures represent promising surrogate markers of senolytic target engagement in human neurodegenerative disorders.

Clinical Implications for Future Geroscience Trials

The exploratory biomarker findings from this phase 1 study provide important foundations for the evolving field of cognitive geroscience. Historically, drug development for Alzheimer's disease focused almost exclusively on directly targeting amyloid beta plaques. However, the multifaceted biology of cellular senescence demands broad biomarker frameworks that evaluate neuroinflammation, secretory mediators, and systemic target engagement simultaneously. While this initial trial involved five participants, the multi-omic approach confirms the feasibility of tracking complex biological signatures. In addition, these observations highlight that senolytics operate through distinct mechanisms compared to monoclonal antibodies. Consequently, senolytics could eventually function as complementary therapies alongside existing disease-modifying agents in clinical practice. For healthcare providers, understanding these emerging fluid biomarkers will prove essential as larger randomized trials advance toward completion. Rigorous independent validation across diverse cohorts remains necessary before these fluid analytes can direct routine patient management. Nevertheless, these exploratory data illuminate the biological consequences of senescent cell clearance in human patients. Ultimately, validated biofluid panels will accelerate the development of targeted therapies designed to preserve cognitive health.

Frequently Asked Questions

What was the primary goal of the exploratory fluid biomarker analysis?

The investigators evaluated senescence and Alzheimer's disease analytes across blood, cerebrospinal fluid, and urine samples. Consequently, these exploratory biofluid measurements help determine whether clearance of senescent cells occurred. Additionally, the data guide the selection of reliable, standardized outcome biomarkers for future interventional senolytic clinical trials.

Did dasatinib and quercetin alter core amyloid and tau pathology?

Mass spectrometry analyses showed that cerebrospinal fluid levels of amyloid beta and tau remained stable throughout the study. Therefore, short-term senolytic administration did not abruptly alter classic Alzheimer's hallmarks. Instead, the intervention primarily influenced peripheral transcriptomic inflammation and specific neuroimmune signaling mediators, warranting longer-term studies to assess direct plaque or tangle clearance.

Why are peripheral blood mononuclear cell changes clinically relevant?

Targeted transcriptomics revealed significant downregulation of key proinflammatory genes, including FOS, JUN, IL1β, IL8, and PTGS2 within peripheral immune cells. Consequently, this observation demonstrates that senolytics can exert meaningful systemic anti-inflammatory actions. Furthermore, peripheral transcriptomic tracking provides an accessible, minimally invasive liquid biopsy tool for monitoring target engagement in neurodegenerative disorders.

Disclaimer: This content is for informational and educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional regarding any medical condition or treatment. Refer to the latest local and national guidelines for clinical practice.

References

1. Garbarino VR et al. Evaluation of exploratory fluid biomarkers from a phase 1 senolytic trial in mild Alzheimer's disease. Neurotherapeutics. 2025 Jul. doi: 10.1016/j.neurot.2025.e00591. PMID: 40274471.
2. Gonzales MM, Garbarino VR, Kautz TF, et al. Senolytic therapy in mild Alzheimer's disease: a phase 1 feasibility trial. Nat Med. 2023;29(10):2481-2488.
3. Kirkland JL, Tchkonia T. Senolytic drugs: from discovery to translation. J Intern Med. 2020;288(5):518-536.